Physician profile
Stuart A Walek
NPI 1124128004
$924.35
in general payments reported to CMS, 2019-2025
16 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $24.35 · 2021: $120 · 2022: $337 · 2023: $78.62 · 2024: $146 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $342.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $301.89 | 2021-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $113.53 | 2022-2023 | Winlevi, Absorica Ld |
| Genzyme Corporation | $94.94 | 2020-2022 | |
| Leo Pharma INC. | $62.40 | 2022-2025 | Adbry |
| Incyte Corporation | $59.34 | 2021-2024 | Opzelura |
| Lilly USA, LLC | $46.19 | 2019-2022 | |
| Amgen INC. | $46.02 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $35.94 | 2019-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $25.48 | 2019 | |
| Medtronic, INC. | $22.63 | 2023 | Venaseal |
| Pfizer INC. | $21.34 | 2022 | |
| Arcutis Biotherapeutics, INC. | $20.78 | 2024 | Zoryve |
| Smith+Nephew, INC. | $20.25 | 2019 | |
| Janssen Biotech, INC. | $19.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.73 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $13.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Walek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.